Hussein K, Bock O, Theophile K, Schulz-Bischof K, Porwit A, Schlue J, Jonigk D, Kreipe H
Institute of Pathology, Hannover Medical School, Hannover, Germany.
Leukemia. 2009 May;23(5):852-5. doi: 10.1038/leu.2008.371. Epub 2009 Feb 5.
The thrombopoietin receptor gene (MPL) is expressed in megakaryocytes and exhibits the gain of function point mutation W515K/L in approximately 5% of patients with primary myelofibrosis/idiopathic myelofibrosis (PMF) representing one subtype of the chronic myeloproliferative disorders (myeloproliferative neoplasm). A series of primary and secondary acute myeloid leukaemias (AML) with megakaryoblastic phenotype and myelofibrosis unrelated to PMF (n=12) was analysed for the MPL(W515K/L) mutation by pyrosequencing. In three cases (25%), MPL(W515L) was found and in two of these a combination with trisomy 21 or the Philadelphia chromosome occurred. None of the secondary AML cases evolving from pre-existing PMF showed MPL(W515K/L) (n=4). We conclude that MPL(W515L) occurs in a considerable proportion of acute megakaryoblastic leukaemias with myelofibrosis unrelated to PMF.
血小板生成素受体基因(MPL)在巨核细胞中表达,在约5%的原发性骨髓纤维化/特发性骨髓纤维化(PMF)患者中表现出功能获得性点突变W515K/L,PMF是慢性骨髓增殖性疾病(骨髓增殖性肿瘤)的一种亚型。通过焦磷酸测序分析了一系列具有巨核细胞表型且与PMF无关的原发性和继发性急性髓系白血病(AML)及骨髓纤维化(n = 12)。在3例(25%)中发现了MPL(W515L),其中2例伴有21号染色体三体或费城染色体。从既往PMF演变而来的继发性AML病例均未显示MPL(W515K/L)(n = 4)。我们得出结论,MPL(W515L)在相当比例的与PMF无关的伴有骨髓纤维化的急性巨核细胞白血病中出现。